| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
| Targets |
L-Aspartic acid sodium does not have a specific molecular target like an enzyme or receptor in the traditional sense. As an amino acid, it is involved in various metabolic pathways. It is a precursor for the synthesis of other amino acids, such as asparagine, and is involved in the urea cycle and gluconeogenesis. L-Aspartic acid sodium has been shown to be a suitable prodrug for colon-specific drug delivery. In this context, the compound is used as a carrier to deliver drugs specifically to the colon. The compound also promotes Na⁺ efflux from rat forebrain membrane vesicles, suggesting that it may interact with sodium transporters or channels. It may also act as a neurotransmitter, possibly by activating NMDA receptors. However, its primary use in research is as a biochemical reagent and a prodrug for colon-specific delivery.
|
|---|---|
| ln Vitro |
In vitro, L-Aspartic acid sodium is used as a biochemical reagent in various assays. It is used to study amino acid metabolism, enzyme activity, and cellular signaling. The compound promotes Na⁺ efflux from rat forebrain membrane vesicles. It has been shown to be a suitable prodrug for colon-specific drug delivery. In this context, the compound is conjugated to a drug, and the conjugate is administered orally. The conjugate is designed to be stable in the upper gastrointestinal tract but is cleaved in the colon by bacterial enzymes, releasing the active drug. This approach can be used to deliver drugs specifically to the colon for the treatment of colonic diseases. The compound's activity in these assays is typically measured by monitoring the release of the drug or by measuring the transport of the compound across cell monolayers.
|
| ln Vivo |
Detailed in vivo activity data for L-Aspartic acid sodium is not extensively reported in the available literature. However, its use as a prodrug for colon-specific drug delivery has been investigated. In such studies, the compound is conjugated to a drug and administered orally to animals. The drug levels in the blood and colon are measured. The efficacy of the drug is assessed in animal models of colonic disease. The compound's ability to promote Na⁺ efflux from rat forebrain membrane vesicles suggests that it may have effects on sodium transport in vivo. However, these effects have not been extensively studied. The compound is primarily used as a research tool and a prodrug.
|
| Enzyme Assay |
Cell-free assays for L-Aspartic acid sodium typically involve studying its role as a substrate or inhibitor in enzymatic reactions. For example, the compound can be used as a substrate for aspartate aminotransferase, which catalyzes the transfer of an amino group from aspartate to α-ketoglutarate. The activity of the enzyme is measured by monitoring the production of oxaloacetate or glutamate. The compound can also be used to study the activity of other enzymes that utilize aspartate, such as asparagine synthetase. These assays are performed in a cell-free system using purified enzymes. The compound's role as a prodrug can be studied by incubating it with colon-specific enzymes, such as azoreductases or glycosidases, and measuring the release of the active drug.
|
| Cell Assay |
For in vitro cellular assays, the effect of L-Aspartic acid sodium on cells is typically assessed by measuring its effects on cell viability, metabolism, or signaling. The compound is used as a nutritional supplement in cell culture media. It is also used to study the transport of amino acids across cell membranes. The compound's ability to promote Na⁺ efflux from rat forebrain membrane vesicles suggests that it may affect ion transport in cells. However, specific cellular assays for L-Aspartic acid sodium are not detailed in the available literature. The compound is primarily used as a reagent in biochemical assays.
|
| Animal Protocol |
In vivo animal experiments involving L-Aspartic acid sodium typically focus on its use as a prodrug for colon-specific drug delivery. In such a study, rats or mice are administered orally a prodrug consisting of a drug conjugated to L-aspartic acid. Blood samples are collected at various time points, and the concentration of the drug in the blood is measured. The animals are euthanized, and the colon is removed to measure the drug levels in the colonic tissue. The efficacy of the prodrug is assessed in animal models of colonic disease, such as colitis or colorectal cancer. The compound's ability to deliver the drug specifically to the colon is evaluated by comparing drug levels in the colon to drug levels in other tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for L-Aspartic acid sodium are not typically reported, as it is not a drug but a biochemical reagent and a prodrug component. When used as a prodrug, the pharmacokinetics of the prodrug and the released drug are studied. The prodrug is designed to be stable in the upper gastrointestinal tract and to be cleaved in the colon. The released drug is then absorbed into the systemic circulation. The pharmacokinetic parameters of the drug, such as half-life, volume of distribution, and clearance, are determined. The compound itself is a natural amino acid and is metabolized through normal amino acid pathways.
|
| Toxicity/Toxicokinetics |
L-Aspartic acid sodium is generally considered to be non-toxic, as it is a natural amino acid. However, as a research chemical, standard safety precautions should be observed when handling this compound. No specific toxicity studies have been detailed in the public domain. The compound is not approved for clinical use as a drug, but it may be used as an excipient in pharmaceutical formulations.
|
| References |
|
| Additional Infomation |
A common non-essential amino acid, existing in its L-form. It is found in both plants and animals, particularly in sugarcane and sugar beets. It may be a neurotransmitter.
L-Aspartic acid sodium is a research tool for studying amino acid metabolism and drug delivery. It is used as a prodrug for colon-specific delivery. It is not a drug. |
| Molecular Formula |
C₄H₆NNAO₄
|
|---|---|
| Molecular Weight |
155.08
|
| Exact Mass |
154.012
|
| CAS # |
3792-50-5
|
| Related CAS # |
L-Aspartic acid;56-84-8;Aspartic acid calcium;10389-09-0;L-Aspartic acid potassium;1115-63-5
|
| PubChem CID |
21806
|
| Appearance |
White to off-white solid powder
|
| Density |
1.514g/cm3
|
| Boiling Point |
264.1ºC at 760 mmHg
|
| Melting Point |
~140 °C (dec.)
|
| Flash Point |
113.5ºC
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@@H](C(=O)[O-])N)C(=O)[O-].[Na+].[Na+]
|
| InChi Key |
XMXOIHIZTOVVFB-JIZZDEOASA-L
|
| InChi Code |
InChI=1S/C4H7NO4.2Na/c5-2(4(8)9)1-3(6)7;;/h2H,1,5H2,(H,6,7)(H,8,9);;/q;2*+1/p-2/t2-;;/m0../s1
|
| Chemical Name |
disodium;(2S)-2-aminobutanedioate
|
| Synonyms |
LAspartic aicd sodium L Aspartic aicd sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~322.41 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4483 mL | 32.2414 mL | 64.4828 mL | |
| 5 mM | 1.2897 mL | 6.4483 mL | 12.8966 mL | |
| 10 mM | 0.6448 mL | 3.2241 mL | 6.4483 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
